• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在初始心肌梗死溶栓分级为0级的ST段抬高型心肌梗死患者中,肾功能不全作为经皮冠状动脉介入治疗后慢血流/无复流现象及ST段回落受损的预测指标。

Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0.

作者信息

Kai Takahiko, Oka Satoshi, Hoshino Katsuomi, Watanabe Kazunori, Nakamura Jun, Abe Makoto, Watanabe Akinori

机构信息

Department of Cardiology, Fujieda Municipal General Hospital.

出版信息

Circ J. 2021 Sep 24;85(10):1770-1778. doi: 10.1253/circj.CJ-21-0221. Epub 2021 Jul 20.

DOI:10.1253/circj.CJ-21-0221
PMID:34305099
Abstract

BACKGROUND

The slow-flow/no-reflow phenomenon and impaired ST segment resolution (STR) following primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) predict unfavorable prognosis and are characterized by obstruction of the coronary microvascular. Several predictors of slow-flow/no-reflow have been revealed, but few studies have investigated predictors of slow-flow/no-reflow and STR exclusively in acute myocardial infarction patients with initial Thrombolysis in Myocardial Infarction (TIMI) Grade 0.

METHODS AND RESULTS

In all, 279 STEMI patients with initial TIMI Grade 0 were enrolled in the study. Slow-flow/no-reflow was defined as TIMI Grade <3 by angiography after PCI, and impaired STR was defined as STR <50% on an electrocardiogram after PCI. Slow-flow/no-reflow was observed in 31 patients. In multivariate analysis, estimated glomerular filtration rate (eGFR; odds ratio [OR] 0.97; P=0.007), a history of cerebrovascular disease (OR 4.65, P=0.007), time to recanalization ≥4 h (OR 2.76, P=0.023), and systolic blood pressure ≤90 mmHg (OR 3.45, P=0.046) were independent predictors of slow-flow/no-reflow. Impaired STR was observed in 102 of 248 patients with TIMI Grade 3. In multivariate analysis, eGFR (OR 0.94, P<0.001) and occlusion of the left anterior descending artery (OR 4.48, P<0.001) were independent predictors of impaired STR; eGFR was the only independent predictor of both slow-flow/no-reflow and impaired STR.

CONCLUSIONS

Renal dysfunction may be related to coronary microvascular dysfunction and obstruction.

摘要

背景

ST段抬高型心肌梗死(STEMI)患者在接受直接经皮冠状动脉介入治疗(PCI)后出现的慢血流/无复流现象以及ST段回落受损(STR)预示着不良预后,其特征为冠状动脉微血管阻塞。已发现一些慢血流/无复流的预测因素,但很少有研究专门调查初始心肌梗死溶栓治疗(TIMI)0级的急性心肌梗死患者中慢血流/无复流和STR的预测因素。

方法与结果

本研究共纳入279例初始TIMI 0级的STEMI患者。慢血流/无复流定义为PCI术后血管造影显示TIMI血流分级<3级,STR受损定义为PCI术后心电图上STR<50%。31例患者出现慢血流/无复流。多因素分析显示,估算肾小球滤过率(eGFR;比值比[OR] 0.97;P=0.007)、脑血管疾病史(OR 4.65,P=0.007)、再灌注时间≥4小时(OR 2.76,P=0.023)以及收缩压≤90 mmHg(OR 3.45,P=0.046)是慢血流/无复流的独立预测因素。248例TIMI 3级患者中有102例出现STR受损。多因素分析显示,eGFR(OR 0.94,P<0.001)和左前降支闭塞(OR 4.48,P<0.001)是STR受损的独立预测因素;eGFR是慢血流/无复流和STR受损的唯一独立预测因素。

结论

肾功能不全可能与冠状动脉微血管功能障碍和阻塞有关。

相似文献

1
Renal Dysfunction as a Predictor of Slow-Flow/No-Reflow Phenomenon and Impaired ST Segment Resolution After Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction With Initial Thrombolysis in Myocardial Infarction Grade 0.在初始心肌梗死溶栓分级为0级的ST段抬高型心肌梗死患者中,肾功能不全作为经皮冠状动脉介入治疗后慢血流/无复流现象及ST段回落受损的预测指标。
Circ J. 2021 Sep 24;85(10):1770-1778. doi: 10.1253/circj.CJ-21-0221. Epub 2021 Jul 20.
2
Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.入院时红细胞分布宽度-血小板比值对接受直接经皮冠状动脉介入治疗的急性ST段抬高型心肌梗死患者无复流现象的预测价值
Cardiol J. 2016;23(1):84-92. doi: 10.5603/CJ.a2015.0070. Epub 2015 Oct 27.
3
Heterogeneity of the No-Reflow Group After Primary Percutaneous Coronary Intervention Due to ST-Segment Elevation Myocardial Infarction - Are There Sex Differences?ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流现象的组间差异:是否存在性别差异?
Cardiovasc Revasc Med. 2022 Apr;37:97-101. doi: 10.1016/j.carrev.2021.06.014. Epub 2021 Jun 17.
4
Quantification Of Thrombus Burden As An Independent Predictor Of Intra-Procedural No-Reflow In Patients With St-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Revascularization.在接受直接经皮冠状动脉血运重建术的 ST 段抬高型心肌梗死患者中,血栓负荷的定量分析作为术中无复流的独立预测因子。
J Ayub Med Coll Abbottabad. 2022 Apr-Jun;34(2):288-294. doi: 10.55519/JAMC-02-9698.
5
Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction.冠状动脉扩张是 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流的独立预测因子。
Int J Cardiol. 2018 Aug 15;265:12-17. doi: 10.1016/j.ijcard.2018.04.120. Epub 2018 Apr 25.
6
Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.ST段抬高型心肌梗死患者入院时单核细胞计数与直接经皮冠状动脉介入治疗后血管造影无复流的相关性。
Kardiol Pol. 2016;74(10):1160-1166. doi: 10.5603/KP.a2016.0065. Epub 2016 May 10.
7
Association between kaolin-induced maximum amplitude and slow-flow/no-reflow in ST elevation myocardial infarction patients treated with primary percutaneous coronary intervention.在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中,高岭土诱导的最大幅度与慢血流/无复流的关系。
Int J Cardiol. 2022 Dec 15;369:13-18. doi: 10.1016/j.ijcard.2022.08.025. Epub 2022 Aug 12.
8
Predictors of No-Reflow Phenomenon in Young Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.接受直接经皮冠状动脉介入治疗的年轻急性ST段抬高型心肌梗死患者无复流现象的预测因素
Angiology. 2016 Aug;67(7):683-9. doi: 10.1177/0003319715605977. Epub 2015 Sep 13.
9
The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.急性ST段抬高型心肌梗死患者接受直接经皮冠状动脉介入治疗时血清类风湿因子水平与无复流现象的关系
J Clin Lab Anal. 2018 Nov;32(9):e22598. doi: 10.1002/jcla.22598. Epub 2018 Jun 26.
10
Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.经皮冠状动脉介入治疗 ST 段抬高型心肌梗死无复流现象的预测因素。
Ann Cardiol Angeiol (Paris). 2021 Jun;70(3):136-142. doi: 10.1016/j.ancard.2021.04.004. Epub 2021 May 4.

引用本文的文献

1
Markers in Acute Coronary Syndrome: Distal Coronary Embolism at Percutaneous Coronary Intervention.急性冠状动脉综合征的标志物:经皮冠状动脉介入治疗时的冠状动脉远端栓塞
J Cardiovasc Dev Dis. 2025 Aug 19;12(8):315. doi: 10.3390/jcdd12080315.
2
PCSK-9 Inhibitors Can Significantly Improve the Coronary Slow Flow Caused by Elevated Lipoprotein (a) in ST-Elevation Myocardial Infarction Patients With Chronic Kidney Disease.前蛋白转化酶枯草溶菌素9(PCSK-9)抑制剂可显著改善慢性肾脏病合并ST段抬高型心肌梗死患者因脂蛋白(a)升高所致的冠状动脉慢血流现象。
Catheter Cardiovasc Interv. 2025 Jul;106(1):396-407. doi: 10.1002/ccd.31543. Epub 2025 Apr 25.
3
Clinical, laboratory, and procedural predictors of slow flow/no reflow phenomenon after emergency percutaneous coronary interventions in ST-elevated myocardial infarction.
ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗后慢血流/无复流现象的临床、实验室及操作预测因素
Egypt Heart J. 2024 Nov 4;76(1):146. doi: 10.1186/s43044-024-00577-0.
4
Association between sarcopenia index, intraoperative events and post-discharge mortality in patients undergoing percutaneous coronary intervention: a retrospective cohort study in a teaching hospital in Western China.中国西部地区一所教学医院接受经皮冠状动脉介入治疗的患者中肌少症指数、术中事件与出院后死亡率的相关性:一项回顾性队列研究。
BMJ Open. 2024 Nov 1;14(10):e082964. doi: 10.1136/bmjopen-2023-082964.
5
Relationship between the Fibrinogen/Albumin Ratio and Microvascular Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction: A Prospective Study.纤维蛋白原/白蛋白比值与 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后微血管灌注的关系:一项前瞻性研究。
Arq Bras Cardiol. 2023 Oct;120(11):e20230002. doi: 10.36660/abc.20230002.
6
Combined Prognostic Value of Preprocedural Protein-Energy Wasting and Inflammation Status for Amputation and/or Mortality after Lower-Extremity Revascularization in Hemodialysis Patients with Peripheral Arterial Disease.术前蛋白质-能量消耗和炎症状态对合并外周动脉疾病的血液透析患者下肢血管重建术后截肢和/或死亡的联合预后价值
J Clin Med. 2023 Dec 25;13(1):126. doi: 10.3390/jcm13010126.
7
Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy.直接经皮冠状动脉介入治疗后的冠状动脉无复流——关于病理生理学、诊断、临床影响及治疗的当前认知
J Clin Med. 2023 Aug 27;12(17):5592. doi: 10.3390/jcm12175592.
8
Predilation Ballooning in High Thrombus Laden STEMIs: An Independent Predictor of Slow Flow/No-Reflow in Patients Undergoing Emergent Percutaneous Coronary Revascularization.高血栓负荷 ST 段抬高型心肌梗死患者的预扩张球囊:急诊经皮冠状动脉血运重建术患者血流缓慢/无复流的独立预测因素。
J Interv Cardiol. 2023 Jan 6;2023:4012361. doi: 10.1155/2023/4012361. eCollection 2023.
9
The Impact of Kidney Function on the Slow-Flow/No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention: Registry Analysis.肾功能对行直接经皮冠状动脉介入治疗患者慢血流/无复流现象的影响:注册分析。
J Interv Cardiol. 2022 Nov 30;2022:5815274. doi: 10.1155/2022/5815274. eCollection 2022.